5-aminolevulinate and CHIL3/CHI3L1 treatment amid ischemia aids liver metabolism and reduces ischemia-reperfusion injury

Guanghui Jin, Na Guo, Yasong Liu, Lele Zhang, Chen Liang, Tao Dong, Wei Liu, Xiaomei Zhang, Yong Jiang, Guo Lv, Fei Zhao, Ziqing Hei, Yang Yang, Jingxing OuTheranostics 2023 · DOI

TL;DR: Supplementing 5-aminolevulinate (5-ALA) during liver ischemia mitigates reperfusion injury by reprogramming macrophage polarization toward an anti-inflammatory M2 state. This metabolic shift, mediated by the downregulation of the CX3CR1 receptor, triggers the secretion of CHIL3/CHI3L1, a protein that hepatocytes internalize to restore lipid metabolism and mitochondrial function.

Abstract: Liver resection and transplantation surgeries are accompanied by hepatic ischemia-reperfusion (HIR) injury that hampers the subsequent liver recovery. Given that the liver is the main organ for metabolism and detoxification, ischemia-reperfusion in essence bestows metabolic stress upon the liver and disrupts local metabolic and immune homeostasis. Most of the recent and current research works concerning HIR have been focusing on addressing HIR-induced hepatic injury and inflammation, instead of dealing with the metabolic reprogramming and restoration of redox homeostasis. As our previous work uncovers the importance of 5-aminolevulinate (5-ALA) synthesis during stress adaptation, here we evaluate the effects of supplementing 5-ALA to mitigate HIR injury. Our results reveal that supplementing 5-ALA promotes macrophagic M2 polarization via downregulation of RelA and CX3CR1 in mice following HIR, while M2 macrophage-produced CHIL3/CHI3L1 also manifests beneficial effects to the recovery of hepatic metabolism. 5-ALA and CHIL3/CHI3L1 together mitigate HIR-induced mitochondrial dysfunction and hepatocellular injuries, which may be developed into safe and effective clinical treatments to attenuate HIR injuries.

Introduction: The Metabolic Challenge of HIR

Hepatic ischemia-reperfusion (HIR) injury is an unavoidable consequence of liver resection and transplantation. When blood flow is stopped (ischemia) and then restored (reperfusion), the liver experiences a massive surge in reactive oxygen species (ROS) and a collapse of metabolic homeostasis. While most research focuses on dampening the resulting inflammatory "firestorm," this paper investigates the metabolic reprogramming required for the liver to recover. The authors look to nature for inspiration—specifically hibernating mammals, which naturally upregulate 5-ALA to survive extreme metabolic stress. They aim to determine if exogenous 5-ALA can act as a metabolic "rescue" signal to prevent the cascade of cell death and dysfunction following HIR.

Methodology

The researchers employed a multi-scale approach combining in vivo mouse models and in vitro human and mouse cell cultures:

  • HIR Mouse Model: A 70% liver ischemia model was used, with 5-ALA administered via intraperitoneal injection during the ischemic phase.
  • Genetic and Cellular Models: Cx3cr1 knockout (KO) mice were used to investigate the role of this specific chemokine receptor. Primary mouse hepatocytes, macrophages, and the human L-02 hepatocyte line were subjected to oxygen-glucose deprivation and reoxygenation (OGD/R) to mimic HIR.
  • Metabolic Profiling: Seahorse assays measured ATP production, metabolic cages tracked whole-animal energy expenditure, and RNA-seq mapped global gene expression changes (OMIX002840, OMIX002841, OMIX002843).
  • Clinical Validation: Paired pre- and post-transplantation liver samples and serum from 20 patients were used to validate the clinical relevance of 5-ALA and CHI3L1 pathways.

Metabolic Reprogramming and Macrophage Cross-talk

The study reveals that the 5-ALA pathway is highly fragile during HIR. The injury naturally suppresses key enzymes in the 5-ALA synthesis pathway, such as ALAD and UROS, leading to a deficiency of downstream metabolites right when the liver needs them most.

Metabolic pathway of 5-ALA in mouse liver during reperfusion, highlighting the downregulation of key enzymes.

A sophisticated "help signal" mechanism was identified: 5-ALA suppresses the RelA-CX3CR1 axis in macrophages, shifting them from a pro-inflammatory (M1) to a pro-healing (M2) state. These M2 macrophages then secrete CHIL3 (CHI3L1 in humans). In a surprising twist, hepatocytes internalize the secreted CHIL3 protein, which then acts directly on mitochondria to boost lipid catabolism and ATP production without increasing oxidative stress.

Key Results

  • Reduced Liver Damage: 5-ALA treatment (30 mg/kg) significantly lowered serum AST, ALT, and LDH levels and reduced the number of apoptotic cells in the liver.
  • Metabolic Restoration: 5-ALA promoted lipid catabolism post-reperfusion, preventing the accumulation of toxic lipid droplets. Quantitative data shows a significant drop in porphobilinogen (PBG) levels during ischemia and reperfusion, which 5-ALA supplementation aims to counteract.
Porphobilinogen levels in mouse liver across sham, ischemia, and reperfusion conditions.
  • Synergistic Protection: While 5-ALA or CHIL3 alone provide some benefit, a combined treatment significantly enhances the recovery of hepatic lipid metabolism and reduces injury markers more effectively than either alone.

Limitations and Future Work

Future work is needed to optimize the therapeutic window and determine if multiple doses are beneficial. Additionally, since 5-ALA is a heme precursor, high doses could theoretically trigger porphyria, requiring careful clinical screening. While the paper shows hepatocytes take up CHIL3, the specific receptor or endocytic pathway responsible for this internalization remains to be fully characterized. Finally, long-term effects on liver regeneration and fibrosis need further investigation beyond the initial 24-hour window.

Summary updated

Abstract

<b>Rationale:</b> Liver resection and transplantation surgeries are accompanied by hepatic ischemia-reperfusion (HIR) injury that hampers the subsequent liver recovery. Given that the liver is the main organ for metabolism and detoxification, ischemia-reperfusion in essence bestows metabolic stress upon the liver and disrupts local metabolic and immune homeostasis. Most of the recent and current research works concerning HIR have been focusing on addressing HIR-induced hepatic injury and inflammation, instead of dealing with the metabolic reprogramming and restoration of redox homeostasis. As our previous work uncovers the importance of 5-aminolevulinate (5-ALA) synthesis during stress adaptation, here we evaluate the effects of supplementing 5-ALA to mitigate HIR injury. <b>Methods:</b> 5-ALA was supplemented into the mice or cultured cells during the ischemic or oxygen-glucose deprivation (OGD) phase. Following reperfusion or reoxygenation, cellular metabolism and energy homeostasis, mitochondrial production of reactive oxygen species (ROS) and transcriptomic changes were evaluated in HIR mouse models or cultured hepatocytes and macrophages. Liver injury, hepatocytic functional tests, and macrophagic M1/M2 polarization were assessed. <b>Results:</b> Dynamic changes in the expression of key enzymes in 5-ALA metabolism were first confirmed in donor and mouse liver samples following HIR. Supplemented 5-ALA modulated mouse hepatic lipid metabolism and reduced ATP production in macrophages following HIR, resulting in elevation of anti-inflammatory M2 polarization. Mechanistically, 5-ALA down-regulates macrophagic chemokine receptor CX3CR1 via the repression of RelA following OGD and reoxygenation (OGD/R). <i>Cx3cr1</i> KO mice demonstrated milder liver injuries and more macrophage M2 polarization after HIR. M2 macrophage-secreted chitinase-like protein 3 (CHIL3; CHI3L1 in human) is an important HIR-induced effector downstream of CX3CR1 deficiency. Addition of CHIL3/CHI3L1 alone improved hepatocellular metabolism and reduced OGD/R-inflicted injuries in cultured mouse and human hepatocytes. Combined treatment with 5-ALA and CHIL3 during the ischemic phase facilitated lipid metabolism and ATP production in the mouse liver following HIR. <b>Conclusion:</b> Our results reveal that supplementing 5-ALA promotes macrophagic M2 polarization via downregulation of RelA and CX3CR1 in mice following HIR, while M2 macrophage-produced CHIL3/CHI3L1 also manifests beneficial effects to the recovery of hepatic metabolism. 5-ALA and CHIL3/CHI3L1 together mitigate HIR-induced mitochondrial dysfunction and hepatocellular injuries, which may be developed into safe and effective clinical treatments to attenuate HIR injuries.
BibTeX
@inproceedings{jin2023aminolevulinate,
  author = {Guanghui Jin and Na Guo and Yasong Liu and Lele Zhang and Chen Liang and Tao Dong and Wei Liu and Xiaomei Zhang and Yong Jiang and Guo Lv and Fei Zhao and Wei Liu and Ziqing Hei and Yang Yang and Jingxing Ou},
  title = {{5-aminolevulinate and CHIL3/CHI3L1 treatment amid ischemia aids liver metabolism and reduces ischemia-reperfusion injury}},
  booktitle = {Theranostics},
  year = {2023},
  doi = {10.7150/thno.83163},
}
Figure